Bioasis Technologies Inc. (OTCPK: BIOA.F)
Health Care · Biotechnology · US
$—
— today · — 1Y
Bioasis Technologies Inc. (OTCPK: BIOA.F) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.94K.
trading between 0.00 and 0.00.
Tweenvest scores Bioasis Technologies Inc. across four factors: quality 22/100, value 44/100, growth 0/100. Its strongest factor is value.
BIOA.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.94K
- Revenue (TTM)
- $199.01K
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 156.10
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 79.41M
- Employees
- —
- Next earnings
- —
About Bioasis Technologies Inc.
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
- ISIN
- CA09064N1033
- Listed since
- Jul 24, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.